Premium
Selectin‐P and interleukin‐8 plasma levels in coronary heart disease patients
Author(s) -
Romuk E.,
SkrzepPoloczek B.,
Wojciechowska C.,
Tomasik A.,
Birkner E.,
Wodniecki J.,
Gabrylewicz B.,
Ochala A.,
Tendera M.
Publication year - 2002
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1046/j.1365-2362.2002.01053.x
Subject(s) - medicine , coronary heart disease , pathogenesis , cardiology , interleukin 6 , interleukin , immune system , heart disease , disease , inflammation , cytokine , immunology
Background Alterations of the immune system are now believed to play crucial role in the pathogenesis of atherosclerosis. The aim of this study was analysis of soluble forms of selectin‐P and interleukin‐8 levels in patients with different form of coronary heart disease. Materials and methods: In the study took part 18 patients with stable coronary heart disease, 20 patients with unstable coronary heart disease and 15 healthy persons from control group. Soluble selectin‐P and interleukin‐8 levels were measured in EDTA plasma with the use of enzyme immunoassay ELISA. Results The level of soluble selectin‐P was significantly higher in unstable coronary heart disease patients in comparison to the stable coronary heart disease patients ( P ≤ 0·01) and nonsignificantly higher in comparison to the control group. The level of interleukin‐8 were significantly higher in unstable coronary heart disease patients in comparison to the stable coronary heart disease patients ( P ≤ 0·01) and in comparison to the control group ( P ≤ 0·02). Conclusion: Our findings suggest that soluble form of selectin‐P and interleukin‐8 may be useful clinical predictors of unstable coronary heart disease. The assessment of the risk for the development of coronary heart disease requires further serial investigation.